Fig. 1: Adjuvants shape vaccine-induced functional antibody responses.
a The boxplots (representing medians, interquartile ranges [IQRs], minima, and maxima) show the antibody features for each vaccine adjuvant group. Groups received HBsAg adjuvanted with AS01B, AS01E, AS03, AS04, or Alum. Samples were profiled at day 30, 60, 360, and 390. Individuals were vaccinated at day 0, with an adjuvanted boost at day 30 and a non-adjuvanted, fractional-dose antigenic challenge at day 360. Measurements are provided as: log10 MFI (mean fluorescence intensity), for the isotypes/subclasses/FcR-binding levels and C1q; as phagocytosis score, for antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), and antibody-dependent dendritic cell phagocytosis (ADDCP); and as percentage of cells that are positive for each activation marker (CD107a, IFN-γ, MIP-1β), for antibody-dependent NK-cell activation (ADNKA). b Each row shows the median values and IQRs for the antibody features at one time point. The measurements were z-scored for each time point and across all adjuvant groups. c The polar plots depict the mean percentile of each antibody feature for each adjuvant group at day 390. Percentile rank scores were determined for each antibody feature across all individuals. d A partial least square discriminant analysis (PLS-DA) model was generated based on LASSO-selected features from all time points and area under the curve (AUC). Each dot represents a vaccinated subject in the PLS-scores plot. Ellipses show 75% confidence regions assuming a multivariate t distribution.
